TrialBlood cells, molecules & diseases2021

Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.

Farid Boulad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.